Reviewing Pfizer (NYSE:PFE) and Inhibitor Therapeutics (OTCMKTS:INTI)

Pfizer (NYSE:PFE) and Inhibitor Therapeutics (OTCMKTS:INTI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares Pfizer and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pfizer	3.62%	10.88%	4.91%
Inhibitor Therapeutics	N/A	141.81%	98.65%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Pfizer and Inhibitor Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	0	11	6	0	2.35
Inhibitor Therapeutics	0	0	0	0	N/A

Pfizer currently has a consensus target price of $36.88, indicating a potential upside of 32.88%. Given Pfizer’s higher probable upside, equities research analysts plainly believe Pfizer is more favorable than Inhibitor Therapeutics.

Insider & Institutional Ownership

68.4% of Pfizer shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Pfizer and Inhibitor Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$58.50 billion	2.69	$2.12 billion	$0.36	77.08
Inhibitor Therapeutics	N/A	N/A	$12.11 million	N/A	N/A

Pfizer has higher revenue and earnings than Inhibitor Therapeutics.

Volatility and Risk

Pfizer has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.81, indicating that its stock price is 181% less volatile than the S&P 500.

Summary

Pfizer beats Inhibitor Therapeutics on 7 of the 10 factors compared between the two stocks.

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.